140 related articles for article (PubMed ID: 11470628)
1. Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C.
Arase Y; Chayama K; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Kobayashi M; Kumada H
Hepatol Res; 2001 Sep; 21(1):55-66. PubMed ID: 11470628
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
3. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
4. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Kobayashi M; Suzuki F; Kumada H
Hepatol Res; 2003 Apr; 25(4):364-370. PubMed ID: 12699846
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
[TBL] [Abstract][Full Text] [Related]
7. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course.
Arase Y; Ikeda K; Chayama K; Murashima N; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Kumada H
J Gastroenterol; 2000; 35(8):607-12. PubMed ID: 10955599
[TBL] [Abstract][Full Text] [Related]
8. Alpha interferon treatment in chronic hepatitis C.
Idéo G; Bellobuono A; Mondazzi L; Tempini S; Bellati G; Idéo GM; Silini E
Clin Exp Rheumatol; 1995; 13 Suppl 13():S167-73. PubMed ID: 8730501
[TBL] [Abstract][Full Text] [Related]
9. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
11. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
[TBL] [Abstract][Full Text] [Related]
12. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
[TBL] [Abstract][Full Text] [Related]
13. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao GB; Ji YY; Xu DZ; Gao J; Wu XH; Zhang QB; Hu DC
Hepatogastroenterology; 1999; 46(26):1059-64. PubMed ID: 10370667
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
16. Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial.
Gaeta GB; Di Virgilio D; Russo G; Stornaiuolo G; Nicolella U; Colella F; Grimaldi M; Pasquale G; Giusti G
J Viral Hepat; 1997 May; 4(3):209-14. PubMed ID: 9181530
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study.
Imai Y; Kawata S; Tamura S; Ito N; Seki K; Nishiuchi M; Shinji Y; Kiriyama K; Himeno S; Minami Y; Kashihara T; Kawakami F; Maeda H; Yabuuchi I; Nishioka M; Shirai Y; Fukuda K; Kiso S; Ito T; Igura T; Doi Y; Matsuzawa Y
Liver; 1997 Apr; 17(2):88-92. PubMed ID: 9138278
[TBL] [Abstract][Full Text] [Related]
18. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
[TBL] [Abstract][Full Text] [Related]
19. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
